Resources-Stratified Guidelines for Classical Hodgkin Lymphoma.
Hodgkin lymphoma
resources-stratified guidelines
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
09 03 2020
09 03 2020
Historique:
received:
19
12
2019
revised:
19
02
2020
accepted:
28
02
2020
entrez:
19
3
2020
pubmed:
19
3
2020
medline:
20
9
2020
Statut:
epublish
Résumé
Hodgkin lymphoma is a haematological malignancy predominantly affecting young adults. Hodgkin lymphoma is a highly curable disease by current treatment standards. Latest treatment guidelines for Hodgkin lymphoma however imply access to diagnostic and treatment modalities that may not be available in settings with restricted healthcare resources. Considerable discrepancies in Hodgkin lymphoma patient survival exist, with poorer outcomes reported in resources-constrained settings. Resources-stratified guidelines for diagnosis, staging and treatment of Hodgkin lymphoma were derived in an effort to optimize patient outcome provided a given setting of available resources. These guidelines were derived based on the framework of the Breast Health Global Initiative stratifying resource levels in basic, core, advanced and maximal categories.
Identifiants
pubmed: 32182952
pii: ijerph17051783
doi: 10.3390/ijerph17051783
pmc: PMC7084688
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Cancer Research UK
ID : 9619
Pays : United Kingdom
Références
Lancet. 1993 Apr 24;341(8852):1051-4
pubmed: 8096958
J Clin Oncol. 2016 Jun 10;34(17):2028-36
pubmed: 27114593
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Haematologica. 2010 Mar;95(3):494-500
pubmed: 19951972
Ann Oncol. 2007 Feb;18(2):376-80
pubmed: 17071938
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv19-iv29
pubmed: 29796651
J Clin Oncol. 1999 Dec;17(12):3776-85
pubmed: 10577849
Lancet. 2012 May 12;379(9828):1791-9
pubmed: 22480758
Blood. 2018 Sep 6;132(10):1013-1021
pubmed: 30049811
Ann Oncol. 2014 Aug;25(8):1622-8
pubmed: 24827123
Clin Oncol (R Coll Radiol). 1994;6(3):147-50
pubmed: 8086347
J Clin Oncol. 2013 Feb 1;31(4):456-60
pubmed: 23248254
J Clin Oncol. 2017 Jun 1;35(16):1786-1794
pubmed: 28291393
J Clin Oncol. 1998 Feb;16(2):584-8
pubmed: 9469345
J Clin Oncol. 1996 Apr;14(4):1297-305
pubmed: 8648387
Hematol Oncol. 2018 Feb;36(1):189-195
pubmed: 28643458
N Engl J Med. 2010 Aug 12;363(7):640-52
pubmed: 20818855
J Clin Oncol. 2016 Jan 1;34(1):6-13
pubmed: 26578608
J Clin Oncol. 2007 Aug 20;25(24):3746-52
pubmed: 17646666
Lancet Oncol. 2019 Feb;20(2):202-215
pubmed: 30658935
J Clin Oncol. 2008 Jan 20;26(3):455-62
pubmed: 18086796
Ann Oncol. 2003 Jan;14(1):91-6
pubmed: 12488299
N Engl J Med. 2018 Jan 25;378(4):331-344
pubmed: 29224502
Blood. 2016 May 5;127(18):2189-92
pubmed: 26834240
Hematology Am Soc Hematol Educ Program. 2009;:497-506
pubmed: 20008235
Lancet. 2015 May 9;385(9980):1853-62
pubmed: 25796459
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
N Engl J Med. 1992 Nov 19;327(21):1478-84
pubmed: 1383821
Lancet. 2018 Dec 23;390(10114):2790-2802
pubmed: 29061295
N Engl J Med. 2012 Feb 2;366(5):399-408
pubmed: 22149921
Pan Afr Med J. 2016 Oct 20;25:99
pubmed: 28292062
N Engl J Med. 2003 Jun 12;348(24):2396-406
pubmed: 12802025
J Natl Compr Canc Netw. 2018 Mar;16(3):245-254
pubmed: 29523663
J Clin Oncol. 2013 Aug 1;31(22):2819-24
pubmed: 23796987
N Engl J Med. 2011 Jul 21;365(3):203-12
pubmed: 21774708
J Clin Oncol. 1998 Mar;16(3):818-29
pubmed: 9508162
Int J Cancer. 2018 Mar 1;142(5):883-890
pubmed: 29023692
Blood. 2000 Apr 1;95(7):2246-52
pubmed: 10733492
J Hematol Oncol. 2019 Oct 22;12(1):107
pubmed: 31640759
J Clin Oncol. 2009 Nov 10;27(32):5390-6
pubmed: 19738111
J Clin Oncol. 2004 Jan 1;22(1):62-8
pubmed: 14657226
J Clin Oncol. 2009 Sep 20;27(27):4548-54
pubmed: 19704068
Rev Bras Hematol Hemoter. 2017 Oct - Dec;39(4):325-330
pubmed: 29150104
Lancet Oncol. 2013 Sep;14(10):943-52
pubmed: 23948348
J Clin Oncol. 2010 Jul 10;28(20):3352-9
pubmed: 20498402
Chest. 2001 Aug;120(2):617-24
pubmed: 11502668
Lancet Oncol. 2018 Oct;19(10):1328-1337
pubmed: 30220622
J Clin Oncol. 2005 Oct 20;23(30):7614-20
pubmed: 16186594
J Clin Oncol. 2016 Jan 1;34(1):27-35
pubmed: 26578607
Lancet. 2015 Apr 11;385(9976):1418-27
pubmed: 25539730
J Clin Oncol. 2007 Aug 10;25(23):3495-502
pubmed: 17606976
J Clin Oncol. 1999 Feb;17(2):534-45
pubmed: 10080597
J Clin Oncol. 2017 Jul 1;35(19):2125-2132
pubmed: 28441111
J Clin Oncol. 2000 Jul;18(13):2615-9
pubmed: 10893294
N Engl J Med. 2015 Apr 23;372(17):1598-607
pubmed: 25901426
J Clin Oncol. 1997 Feb;15(2):528-34
pubmed: 9053474
Mediterr J Hematol Infect Dis. 2014 Jul 01;6(1):e2014048
pubmed: 25045456
Int J Cancer. 1997 Feb 7;70(4):375-82
pubmed: 9033642
Lancet. 2002 Jun 15;359(9323):2065-71
pubmed: 12086759
J Clin Oncol. 2009 Feb 10;27(5):805-11
pubmed: 19124807
J Clin Oncol. 2012 Jun 20;30(18):2183-9
pubmed: 22454421
N Engl J Med. 2016 Jun 23;374(25):2419-29
pubmed: 27332902
Indian J Med Paediatr Oncol. 2015 Oct-Dec;36(4):255-60
pubmed: 26811596
Haematologica. 2011 Nov;96(11):1692-9
pubmed: 21828120
N Engl J Med. 2010 Aug 12;363(7):653-62
pubmed: 20818856
Leuk Lymphoma. 2008 Oct;49(10):1854-9
pubmed: 18949609
Cancer. 1975 Jul;36(1):252-9
pubmed: 54209
Int J Cancer. 2013 Aug 1;133(3):687-94
pubmed: 23335127
J Clin Oncol. 2016 Jun 10;34(17):2020-7
pubmed: 27069074
J Clin Oncol. 2005 Mar 1;23(7):1522-9
pubmed: 15632410
Blood. 2004 Dec 1;104(12):3483-9
pubmed: 15315964
Breast J. 2006 Jan-Feb;12 Suppl 1:S3-15
pubmed: 16430397